Tag Archives: Roche Tissue Diagnostics

Feb. 14, 2024—Roche announced it has entered into an agreement with PathAI to develop AI-enabled digital pathology algorithms for Roche Tissue Diagnostics’ companion diagnostics business.

Aug. 30, 2019—Roche announced the expanded use of its Ventana PD-L1 (SP142) Assay in triple-negative breast cancer for patients living in CE markets where Tecentriq is approved. It is the first companion diagnostic to aid in identifying triple-negative breast cancer patients eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy (nab-paclitaxel). The announcement follows the FDA approval of the assay in March as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the Tecentriq combination.